New study bolsters recommendations to base initial treatment on clinical response One long-term study reported in 2024 showed that outcomes from early TTT were still good as long as 20 years after starting therapy, although it involved participants in two separate Dutch trials that used different TTT strategies. The current study followed participants in a Norwegian trial called ARCTIC, whose initial results were reported in 2016. It enrolled 230 patients who were randomized to two similar TTT strategies: both had clinical remission as the target, but one also included completely negative ultrasound findings of inflammation at all joints tested. Moreover, the median change in modified van der Heijde-Sharp score for radiographic damage was just 2.0 points (IQR 0.5-4.5). With scores averaging 0.5 at baseline, and a maximum possible score of 448, the authors called this degree of progression "limited" in their report, appearing in Annals of the Rheumatic Diseases. These findings, the investigators wrote, "support current treatment recommendations for RA and offer reassurance to patients newly diagnosed with RA that clinical remission, preserved function, and favorable long-term survival are realistic long-term outcomes." This study examined 10-year outcomes among participants in a stringent treat-to-target trial, with data from 82% of survivors from the original enrollment. More than 80% were in clinical remission at year 10, with "limited" radiographic progression during follow-up. Most patients with rheumatoid arthritis (RA) whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. Those who had achieved clinical remission (DAS <1.6) at year 2 were significantly more likely to keep that status at year 10 (89.9%), compared with those with poorer short-term outcomes (73.1%, P=0.01). Other outcomes including the more conventional 28-joint DAS, ultrasound findings, ACR/EULAR 2.0 remission, and measures of systemic inflammation all showed significantly more disease activity at year 10, albeit still generally low, among those not reaching remission at year 2.

Original title: “Excellent 10-Year Outcomes After Early Treat-to-Target in Rheumatoid Arthritis | MedPage Today”

risk of demyelinating events associated with tnf inhibitors compared with conventional synthetic disease modifying anti rheumatic drugs in rheumatoid arthritis results from the french national health data system

Original title: “Risk of demyelinating events associated with TNF-inhibitors compared with conventional synthetic disease modifying anti-rheumatic drugs in rheumatoid arthritis: results from the French National Health Data System.”

Methotrexate is prescribed to roughly ... Disease Modifying Antirheumatic Drugs, which increase the risk of serious side effects and multiply treatment costs. Amplio’s hypothesis is that MTX fails many patients not because methotrexate does not work, but because too little of it is retained inside the cells that drive inflammation. The Phase 1b results directly support that hypothesis. “It is rare for a Phase ... Methotrexate is prescribed to roughly four out of five newly diagnosed RA patients, yet in only about 40% disease remission is achieved on methotrexate alone.[1, 2] The remaining 60% need add-on second-line biologics or targeted synthetic Disease Modifying Antirheumatic Drugs, which increase the risk of serious side effects and multiply treatment costs. Amplio’s hypothesis is that MTX fails many patients not because methotrexate does not work, but because too little of it is retained inside the cells that drive inflammation. The Phase 1b results directly support that hypothesis. “It is rare for a Phase 1b study to give such a clear read-out on the biomarker that matters. The question we now need to answer is whether more active methotrexate inside the cell translates into more patients reaching remission faster on first-line therapy. If it does, the impact on patients and on healthcare budgets in Europe and the United States would be substantial.” · Phase 1b study design and results The Phase 1b study was an open-label study in 12 patients with rheumatoid arthritis on stable weekly methotrexate (15 to 25 mg), conducted in the Netherlands under an approved clinical trial application (Site: CHDR, Leiden). NovoBioJect is an investigational therapy and has not been approved by any regulatory authority. A single dose of NovoBioJect increased the active form of methotrexate inside patients' immune cells by 38%, a first step toward a potential next-generation first-line treatment for rheumatoid arthritis · First clinical proof of principle. Up to 60% of patients do not achieve remission on methotrexate alone and move on to second-line therapies that cost many times more. NovoBioJect is designed to raise the first-line response rate with potential cost savings for society. AMSTERDAM, the Netherlands, October 1st, 2026 – Amplio Pharma (“Amplio”), a clinical-stage pharmaceutical company developing NovoBioJect to improve first-line treatment of rheumatoid arthritis (RA), today announced positive results from its Phase 1b study of NovoBioJect in patients with RA.

Original title: “Amplio Pharma Reports Positive Early Clinical Results for NovoBioJect, Designed to Make the World's Most-Used Rheumatoid Arthritis Drug Work for More Patients - BioSpace”

New indication adds oral option for young patients

Original title: “AbbVie wins EU approval for paediatric pJIA use”

new humanised tcr transgenic mouse model to study t cells reactive to citrullinated tenascin c a relevant autoantigen in rheumatoid arthritis

Original title: “A new humanised TCR transgenic mouse model to study T cells reactive to citrullinated tenascin C, a relevant autoantigen in rheumatoid arthritis.”

giant abdominal haematoma and rapid multidrug resistant infection after low molecular weight heparin in a patient with covid 19 and rheumatoid arthritis

Original title: “Giant Abdominal Haematoma and Rapid Multidrug-Resistant Infection After Low-Molecular-Weight Heparin in a Patient With COVID-19 and Rheumatoid Arthritis.”

effectiveness and safety of janus kinase inhibitors in patients with rheumatoid arthritis results from a multicenter observational real life girrcs gruppo italiano di ricerca in reumatologia clinica e sperimentale study

Original title: “Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational "real-life" GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.”

comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids a propensity score matched retrospective cohort study

Original title: “Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study.”

case of rheumatoid arthritis presenting with airway obstruction from cricoarytenoid arthritis

Original title: “A Case of Rheumatoid Arthritis Presenting With Airway Obstruction From Cricoarytenoid Arthritis.”

analysis of vaccine adverse events associated with rheumatoid arthritis a pharmacovigilance study based on the vaers database

Original title: “Analysis of vaccine adverse events associated with rheumatoid arthritis: A pharmacovigilance study based on the VAERS database.”

rheumatoid arthritis and multisite cardiac aneurysms involving the lvot valves and intervalvular fibrosa a case based systematic review

Original title: “Rheumatoid arthritis and multisite cardiac aneurysms involving the LVOT, valves, and intervalvular Fibrosa: A case-based systematic review.”

pubic symphysis osteomyelitis presenting as groin pain in a patient with rheumatoid arthritis a case report

Original title: “Pubic symphysis osteomyelitis presenting as groin pain in a patient with rheumatoid arthritis: a case report.”

clinical features anti neutrophil cytoplasmic antibody anca status and human leucocyte antigen hla phenotypes of patients diagnosed with both rheumatoid arthritis and granulomatosis with polyangiitis a case series of six patients with predominant myeloperoxidase mpo anca positivity and hla dr4 dq8 dpb1 04 01 phenotype

Original title: “Clinical features, anti-neutrophil cytoplasmic antibody (ANCA) status, and human leucocyte antigen (HLA) phenotypes of patients diagnosed with both rheumatoid arthritis and granulomatosis with polyangiitis: a case series of six patients with predominant myeloperoxidase (MPO)-ANCA positivity and HLA-DR4/DQ8/DPB1*04:01 phenotype.”

/PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company advancing novel oral immunotherapies for autoimmune diseases, today announced the... ROCKVILLE, MD, June 2, 2026 /PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company advancing novel oral immunotherapies for autoimmune diseases, today announced the completion of full enrollment in the 4-week dose expansion cohort of its Phase 1b clinical trial (NCT05961592) evaluating orally dosed R-2487 in patients with active rheumatoid arthritis (RA). This recommendation marks an important advancement for the R-2487 clinical program and enables continued evaluation of the therapy over an extended treatment period. Data from the 4-week dose expansion cohort will be presented at upcoming national and international rheumatology and immunology conferences, as appropriate and as analyses become available. Dr. Fanger added: "In parallel with the ongoing clinical expansion cohorts evaluating extended dosing and enrolling patients with overlapping RA and Sjögren's disease, we are preparing R-2487 for the next stage of clinical development. This includes advancing clinical protocol design, dose selection strategy, and regulatory engagement to support a Phase 2 clinical evaluation. We are also scaling key operational capabilities, including GMP manufacturing, to enable an efficient transition into the next phase of development for this program." RA is a multi-billion-dollar global market with continued demand for therapies that combine early intervention, improved tolerability, and disease-modifying potential. With internal GMP manufacturing capabilities and a growing clinical pipeline, Rise Therapeutics is positioned to advance multiple programs targeting autoimmune and inflammatory diseases while pursuing value-creating partnerships and strategic growth opportunities, including the continued advancement of R-2487 into Phase 2 clinical development.

Original title: “Rise Therapeutics Completes Enrollment in Four-Week Dose Expansion Cohort for the R-2487 Rheumatoid Arthritis Clinical Trial”

pyoderma gangrenosum as a manifestation of multisystem autoimmunity in a patient with giant cell arteritis optic neuritis and rheumatoid arthritis

Original title: “Pyoderma gangrenosum as a manifestation of multisystem autoimmunity in a patient with giant cell arteritis, optic neuritis and rheumatoid arthritis.”

beyond categorical exclusion reclaiming clinical judgment in the use of jak inhibitors for rheumatoid arthritis

Original title: “Beyond categorical exclusion: Reclaiming clinical judgment in the use of JAK inhibitors for rheumatoid arthritis.”

case of bilateral but not unilateral insufficient calcaneus fractures in a patient with rheumatoid arthritis suffering from talalgia

Original title: “A case of bilateral but not unilateral insufficient calcaneus fractures in a patient with rheumatoid arthritis suffering from talalgia.”

seropositive rheumatoid arthritis with concomitant mri confirmed sacroiliitis in an 18 year old saudi female a case report of diagnostic and therapeutic challenges

Original title: “Seropositive rheumatoid arthritis with concomitant MRI confirmed sacroiliitis in an 18-year-old Saudi female: A case report of diagnostic and therapeutic challenges.”

oral colonization of pneumocystis jirovecii in patients with rheumatoid arthritis and respiratory symptoms a substudy of the aurora cohort

Original title: “Oral colonization of Pneumocystis jirovecii in patients with rheumatoid arthritis and respiratory symptoms: a substudy of the AURORA cohort.”